Discover an informative webinar exploring the impact of osmolality in bioprocessing and in correlation with immunoglobulin G (IgG) production. Osmolality is described as the measurement of the contribution of all the dissolved solutes to the osmotic pressure of a solution. In biopharma, osmolality is usually used as a critical quality control (QC) check for cell culture media, buffers and formulated drug products. It is also used as a critical process parameter during upstream cell culture and downstream filtration.
The Cell Technology group at the National Institute for Bioprocessing Research and Training (NIBRT) focuses on the development of bioprocesses using mammalian cells to produce recombinant proteins, monoclonal antibodies and viral vaccines. There is also a particular interest in the bioprocess conditions that can be used to control the biochemical structure and the post-translational modifications of glycoproteins and hence the quality of biopharmaceuticals.
Osmolality is routinely used in the Cell Technology group as a QC tool, similar to the routine application in the biopharma industry. However, osmolality is applied as an experimental measurement to correlate with IgG production, nutrient depletion studies and bioprocessing applications.
In this webinar, the featured speaker will describe the impact of osmolality assessment in correlation with IgG production when examining the effect of plant protein hydrolysates as additives, in a media development project. When examining the effect of changing media composition to affect IgG glycosylation, osmolality was tracked and correlated with growth and productivity.
In the investigation into the recoverability of cells at various stages of nutrient depletion, osmolality measurements were utilized to correlate the suitability of culture conditions in ‘re-fed’ media, vs. controls of complete media. These preliminary investigations are in the process of being scaled up to the bioreactor level (bench scale) where osmolality validation will be used on samples taken in at-line process analytical technology (PAT) instrumentation development.
Join this webinar to gain insights into osmolality in correlation with IgG production in a media development project.
Dr. James Flynn, Research Scientist, National Institute for Bioprocessing Research and Training (NIBRT)
James Flynn joined the Cell Technology group in NIBRT under the supervision of Prof. Michael Butler as a post-doctoral researcher in May 2022. He is working on an enterprise Ireland-funded project entitled “Development of a robust optical system for on-line real-time analysis of mammalian cells during a bioprocess” with J.M Canty Ltd. James received a BS in Industrial Biochemistry from the University of Limerick in 2017, after which he completed and was awarded a PhD in antimicrobial biomaterials in 2021, from the University of Limerick, under the supervision of Prof. Sarah Hudson.
Prior to joining NIBRT, James continued working as an instrument scientist in the Bernal Institute (UL) bio labs, where he was responsible for the analysis of commercial and academic samples in MALDI TOF MS and chromatographic analysis of proteins, peptides and synthetic polymers and day to day lab management duties. He has accumulated extensive experience in protein/peptide analysis, microbiology, mammalian cell culture and analytical characterization.
Thaïs McNamara, Research Associate, National Institute for Bioprocessing Research and Training (NIBRT)
Thaïs McNamara joined our Cell Technology Group in 2022 as a Research Associate on the EI funded collaborative project with NIBRT, Kerry and Valitacell. Thais received a Bachelor of Science degree in microbiology and biochemistry from the University of Galway in 2021. She then continued to complete an MSc in cellular manufacturing and therapy also from the University of Galway. Thais has joined an active research team at NIBRT investigating the biomanufacturing potential of using plant hydrolysates for the high productivity of therapeutics including monoclonal antibodies.
Kendal Studd, Field Application Specialist, Advanced Instruments
Kendal specializes in advancing novel osmolality applications within the biopharma industry. She is an experienced scientist with a demonstrated history of working in the biotechnology industry within a validation laboratory setting. She graduated from the University of Portsmouth with Distinction in a research Masters’ degree in the Forensic Biology field.
Who Should Attend?
This webinar will appeal to professionals in the following fields:
- Bioprocess Scientists
- Cell Culture Scientists
- Protein Production Scientists
What You Will Learn
Attendees will gain insights into:
- The role of monitoring osmolality in bioprocessing research
- Seeing the potential placement of osmolality measurement in cell culture media development
- Utilising osmolality analysis in Chinese hamster ovary (CHO) cell health studies
- Current uses and future potential for osmolality analysis at the upstream and downstream stages of bioprocessing
Advanced Instruments is a global company offering a novel portfolio of analytical tools including, OsmoTECH®, a robust line of micro-osmometers to support bioprocessing and quality control (QC), and Solentim, a portfolio of best in class imaging and single-cell deposition technologies for cell line development workflows and assurance of clonality for regulatory bodies.